Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

Research Watch

Wilms Tumor–Associated ENL Mutants Cause Target-Gene Overexpression

DOI: 10.1158/2159-8290.CD-RW2020-004 Published February 2020
  • Article
  • Info & Metrics
  • PDF
Loading
  • Major Finding: Wilms tumor–linked ENL mutations cause dysfunctional nephrogenesis and target-gene hyperactivation.

  • Mechanism: Tumor-associated ENL mutations cause increased self-association of ENL at target genes.

  • Impact: This study suggests a causative role of ENL mutations in Wilms tumor and shows a possible mechanism.


Embedded Image

Recurrent hotspot mutations in the histone acetylation–reading YEATS domain of the eleven-nineteen leukemia protein (ENL) have been linked to Wilms tumor, a form of kidney cancer that almost exclusively affects children. However, whether the development of Wilms tumor is directly caused by these mutations, which consistently involve small in-frame insertions or deletions, is not known. In experiments using human kidney cell lines, Wan and colleagues found that these mutations in ENL's YEATS domain led to an apparent gain of function, increasing the transcription of ENL's target genes, some of which, such as HOXA genes, are involved in development. Experiments employing a three-dimensional model of nephrogenesis demonstrated that these mutations caused aberrant nephron development, increasing the abundance of undifferentiated structures that resemble the blastema components of Wilms tumors. Mechanistically, mutant ENL largely bound the same target genes as wild-type ENL, but mutant ENL's occupancy—as well as the occupancy of the larger protein complex ENL joins to activate transcription—was increased at some of those genes, including the HOXA cluster. Interestingly, like wild-type ENL, tumor-associated ENL mutants required the protein's reader function to drive localization to target genes, but the ENL mutants did not appear to have greater affinity for acetylated (or otherwise acylated) histone peptides, implying that increased binding strength did not explain the mutants' increased occupancy at these genes. Instead, tumor-associated ENL mutants exhibited greater self-association at target sequences, which may explain the increased expression of target genes caused by mutant ENL. This self-association–induced gene activation appeared to be driven not only by the mutant YEATS domain, but also by ENL's ANC1 homology domain and a predicted intrinsically disordered region. Collectively, these findings provide preliminary evidence for a causative role of tumor-associated ENL mutations and Wilms tumor, elucidate the mechanism by which these mutations may trigger dysfunctional development, and adds further evidence illustrating the importance of readers of histone modifications in disease.

Wan L, Chong S, Xuan F, Liang A, Cui X, Gates L, et al. Impaired cell fate through gain-of-function mutations in a chromatin reader. Nature 2020;577:121–6.

Notes

Note: Research Watch is written by Cancer Discovery editorial staff. Readers are encouraged to consult the original articles for full details. For more Research Watch, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/CDNews.

  • ©2020 American Association for Cancer Research.
PreviousNext
Back to top
Cancer Discovery: 10 (2)
February 2020
Volume 10, Issue 2
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Wilms Tumor–Associated ENL Mutants Cause Target-Gene Overexpression
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Wilms Tumor–Associated ENL Mutants Cause Target-Gene Overexpression
Cancer Discov February 1 2020 (10) (2) 174; DOI: 10.1158/2159-8290.CD-RW2020-004

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Wilms Tumor–Associated ENL Mutants Cause Target-Gene Overexpression
Cancer Discov February 1 2020 (10) (2) 174; DOI: 10.1158/2159-8290.CD-RW2020-004
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Notes
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Research Watch

  • In Vivo CRISPR Screen Identifies FLI1 as Regulator of Effector T Cells
  • Trial Supports Combination Treatment and New Target for Multiple Myeloma
  • Mitochondrial DNA Damage Triggers an IFN-Mediated Immune Response
Show more Research Watch

Epigenetics

  • Computational Tool Characterizes Previously Unidentified Tumor Subtypes
  • FBXO44 Silences Repetitive Elements during DNA Replication in Cancer
  • H1 Loss Increases Accessibility of Stemness Genes to Drive Lymphoma
Show more Epigenetics
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement